0.53
+0.0052(+0.98%)
Currency In USD
| Previous Close | 0.53 |
| Open | 0.53 |
| Day High | 0.56 |
| Day Low | 0.53 |
| 52-Week High | 1.4 |
| 52-Week Low | 0.25 |
| Volume | 6.25M |
| Average Volume | 5.33M |
| Market Cap | 403.47M |
| PE | -4.86 |
| EPS | -0.11 |
| Moving Average 50 Days | 0.62 |
| Moving Average 200 Days | 0.56 |
| Change | 0.01 |
If you invested $1000 in Senseonics Holdings, Inc. (SENS) since IPO date, it would be worth $164.58 as of June 05, 2025 at a share price of $0.535. Whereas If you bought $1000 worth of Senseonics Holdings, Inc. (SENS) shares 5 years ago, it would be worth $1,121.38 as of June 05, 2025 at a share price of $0.535.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Senseonics Holdings, Inc. to Host In-Person and Virtual Analyst Event at ADA 2025: Eversense® 365 Continuous Glucose Monitoring System for People with Diabetes
GlobeNewswire Inc.
Yesterday at 8:05 PM GMT
GERMANTOWN, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for
Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters’ Option to Purchase Additional Shares, and Closing of Private Placement
GlobeNewswire Inc.
May 21, 2025 9:06 PM GMT
Public offering results in gross proceeds of $57.5 millionPrivate placement results in gross proceeds of approximately $20.3 million GERMANTOWN, Md., May 21, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical techno
Senseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private Placement
GlobeNewswire Inc.
May 16, 2025 3:12 AM GMT
GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for p